A camelid single-domain antibody neutralizes botulinum neurotoxin A by blocking host receptor binding
Abstract Antibody treatment is currently the only available countermeasure for botulism, a fatal illness caused by flaccid paralysis of muscles due to botulinum neurotoxin (BoNT) intoxication. Among the seven major serotypes of BoNT/A-G, BoNT/A poses the most serious threat to humans because of its...
Guardado en:
Autores principales: | Guorui Yao, Kwok-ho Lam, Jasmin Weisemann, Lisheng Peng, Nadja Krez, Kay Perry, Charles B. Shoemaker, Min Dong, Andreas Rummel, Rongsheng Jin |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/28d488b3904246b2b17c6304fa26a9f6 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
A viral-fusion-peptide-like molecular switch drives membrane insertion of botulinum neurotoxin A1
por: Kwok-ho Lam, et al.
Publicado: (2018) -
Genetically engineered red cells expressing single domain camelid antibodies confer long-term protection against botulinum neurotoxin
por: Nai-Jia Huang, et al.
Publicado: (2017) -
On Botulinum Neurotoxin Variability
por: Cesare Montecucco, et al.
Publicado: (2015) -
Botulinum neurotoxin heavy chain belt as an intramolecular chaperone for the light chain.
por: Axel T Brunger, et al.
Publicado: (2007) -
Characterization of immune response induced against catalytic domain of botulinum neurotoxin type E
por: Priyanka Sonkar, et al.
Publicado: (2020)